Antiviral material, antiviral film, antiviral fiber, and antiviral product
First Claim
Patent Images
1. An antiviral film, comprising:
- tungsten oxide microparticles having a mean primary particle diameter (D50) in a range of 5.5 to 75 nm, the mean primary particle diameter (D50) being a D50 diameter of integrated diameter with reference of volumes of 50 pieces or more of microparticles extracted from an image analysis of a SEM or TEM photograph of the microparticles; and
an inorganic binder for binding the tungsten oxide microparticles, a content of the inorganic binder in the antiviral film being from 5 to 95 mass %, and the inorganic binder being made only of an amorphous metal oxide,wherein in a X-ray diffraction chart when the tungsten oxide microparticles are measured by X-ray diffractometry, an intensity ratio of a peak A to a peak D (A/D) and an intensity ratio of a peak B to the peak D (B/D) are in a range of 0.7 to 2.0, and an intensity ratio of a peak C to the peak D (C/D) is in a range of 0.5 to 2.5, wherein the peak A is a peak existing in 2θ
range from 22.8 to 23.4°
, the peak B is a peak existing in 2θ
range from 23.4 to 23.8°
, the peak C is a peak existing in 2θ
range from 24.0 to 24.25°
, and the peak D is a peak existing in 26 range from 24.25 to 24.5°
,wherein the tungsten oxide microparticles contain 15% or more of microparticles having a primary particle diameter of 40 nm or less,wherein a thickness of the antiviral film is in a range of from 2 to 400 nm, andwherein the tungsten oxide microparticles have an inactivation effect R of 2 or more, as expressed by following;
R=log C−
log A wherein C denotes a virus titer tissue culture infective dose (TCID50) obtained after irradiating an unprocessed specimen with visible light for 24 hours, and A denotes a virus titer TCID50 obtained when the specimen is tested in the following manner;
a) said microparticles are adhered to a specimen in a range of 0.01 mg/cm 2 to 40 mg/cm2;
b) the specimen from step (a) is inoculated by a virus titer, wherein said virus is selected from a pathogenic avian influenza virus H9N2, H5N1, and a swine influenza virus;
c) said inoculated specimen from step (b) is irradiated with visible light having a wavelength of 380 nm or more and an illuminance of 6000 lx for 24 hours using a white fluorescent lamp and an ultraviolet cutting filter, and then evaluated for antibacterial activity of photocatalytic products under photoirradiation by Test method JIS-R-1702 (2006).
0 Assignments
0 Petitions
Accused Products
Abstract
In one embodiment, an antiviral material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles. The microparticles have an inactivation effect R of 1 or more expressed by [R=log C−log A], when there is evaluated a virus titer by inoculating on a specimen to which the microparticles are adhered, at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating the specimen with visible light having a wavelength of 380 nm or more and illuminance of 6000 lx. for 24 hours.
19 Citations
13 Claims
-
1. An antiviral film, comprising:
-
tungsten oxide microparticles having a mean primary particle diameter (D50) in a range of 5.5 to 75 nm, the mean primary particle diameter (D50) being a D50 diameter of integrated diameter with reference of volumes of 50 pieces or more of microparticles extracted from an image analysis of a SEM or TEM photograph of the microparticles; and an inorganic binder for binding the tungsten oxide microparticles, a content of the inorganic binder in the antiviral film being from 5 to 95 mass %, and the inorganic binder being made only of an amorphous metal oxide, wherein in a X-ray diffraction chart when the tungsten oxide microparticles are measured by X-ray diffractometry, an intensity ratio of a peak A to a peak D (A/D) and an intensity ratio of a peak B to the peak D (B/D) are in a range of 0.7 to 2.0, and an intensity ratio of a peak C to the peak D (C/D) is in a range of 0.5 to 2.5, wherein the peak A is a peak existing in 2θ
range from 22.8 to 23.4°
, the peak B is a peak existing in 2θ
range from 23.4 to 23.8°
, the peak C is a peak existing in 2θ
range from 24.0 to 24.25°
, and the peak D is a peak existing in 26 range from 24.25 to 24.5°
,wherein the tungsten oxide microparticles contain 15% or more of microparticles having a primary particle diameter of 40 nm or less, wherein a thickness of the antiviral film is in a range of from 2 to 400 nm, and wherein the tungsten oxide microparticles have an inactivation effect R of 2 or more, as expressed by following;
R=log C−
log Awherein C denotes a virus titer tissue culture infective dose (TCID50) obtained after irradiating an unprocessed specimen with visible light for 24 hours, and A denotes a virus titer TCID50 obtained when the specimen is tested in the following manner; a) said microparticles are adhered to a specimen in a range of 0.01 mg/cm 2 to 40 mg/cm2; b) the specimen from step (a) is inoculated by a virus titer, wherein said virus is selected from a pathogenic avian influenza virus H9N2, H5N1, and a swine influenza virus; c) said inoculated specimen from step (b) is irradiated with visible light having a wavelength of 380 nm or more and an illuminance of 6000 lx for 24 hours using a white fluorescent lamp and an ultraviolet cutting filter, and then evaluated for antibacterial activity of photocatalytic products under photoirradiation by Test method JIS-R-1702 (2006). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
Specification